“Faricimab Shown to Be Non-Inferior or Superior for Macular Thickness Improvement in Age-Related Macular Degeneration and Diabetic Macular Edema, with Longer Dosing Intervals: Meta-Analysis of Four Randomized Clinical Trials” A shorter, simplified title for the text could be: “Faricimab Superior for Macular Thickness Improvement in AMD and DME”